Answers are grounded in this paper and cite their sources.
Chronic metabolic illnesses, like diabetes mellitus, have become diseases that harm human health and are now one of the most critical public health problems in almost half a century, as a result of societal development and lifestyle changes. For decades, conventional insulin therapy has been playing a significant role while treating millions of patients around the globe. Unfortunately, despite breakthroughs in DNA recombinant technology and pharmacotherapy, these therapeutic goals are rarely met, and results have not improved significantly. The low effectiveness rate of insulin treatment is becoming recognized as a result of intra-individual and inter-individual differences in insulin needs. Thus, our review focuses on finding superior insulin derivatives to treat diabetes more effectively and efficiently. Insulin analogs hold the potential to overcome the limitations of conventional insulin. We have taken a deep dive into rapid acting and long-acting analogs by discussing their pharmacokinetics, pharmacodynamics, dosage and therapeutic efficacy. But their safety profile has been questioned several times and therefore we have thrown some light on the current innovation trends that are being scrutinized.
No takes yet. Share an insight, caveat, or question.
Oak et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: